HUA MEDICINE announced the completion of two clinical studies

Zhitong
2024.11.30 10:04

HUA MEDICINE's CEO Chen Li announced today at the 9th Pharmaceutical Innovation and Investment Conference the completion of two clinical studies: First, the SENSITIZE 2 study, conducted in collaboration with Professor Juliana Chan's team from The Chinese University of Hong Kong, has been successfully completed. The results show that "using high glucose clamp technology, a single dose of Dapagliflozin restores GK enzyme activity and significantly improves the second-phase insulin secretion and β-cell glucose sensitivity in individuals with glucose tolerance abnormalities"; Second, the Phase I clinical study of the second-generation glucose kinase activator conducted in the United States has been completed, with results indicating that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to that of Dapagliflozin tablets at 75mg BID. The company will further optimize the formulation and conduct multiple ascending dose clinical development of the second-generation GKA in China and the United States to achieve better therapeutic effects. Note: The second-generation GKA is the prodrug of HUA MEDICINE's new diabetes drug Dapagliflozin

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.